|
Cleveland BioLabs and Sabby Announce Resolution of Litigation
MarketWatch The Parties have also agreed that Sabby will return to the Company for cancellation the Series B warrants for 2,049,180 shares of common stock at an exercise price of $1.22 per share that it received in connection with the January 2014 transaction. |
